Program
QL1206
Its studies are mostly in Osteoporosis · Neoplasm Metastasis · Osteoporosis, Postmenopausal, led by Qilu Pharmaceutical.
Furthest: phase 3, since Sep 25, 20195 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 51 open or running | phase 3since Sep 25, 2019 | Aug 21, 2018 | Jan 2027phase 3 · NCT07062978 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2018First study: phase 1 study in Healthy PeopleFirst studyNCT03651947 · 168 enrolled · China
- Sep 25, 2019Phase 3 study in Osteoporosis, PostmenopausalNCT04128163 · 440 enrolled · China
- Dec 10, 2019Phase 1 study in Healthy PeopleNCT04213105 · 144 enrolled · China
- Sep 1, 2020Phase 3 study in Bone MetastasesNCT04550949 · 700 enrolled · China
- Jul 3, 2025Phase 3 study in Postmenopausal Women With Osteoporosis at High Risk of FractureNCT07062978 · 278 planned · China
Ahead
- Jan 2027Primary completion: phase 3 study in Postmenopausal Women With Osteoporosis at High Risk of FractureNCT07062978
TargetBeta
TNFSF11 →read by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF11
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07062978Postmenopausal Women With Osteoporosis at High Risk of Fracture · China | 3 | Recruiting | Jan 2027 | 278 |
| NCT04550949Bone Metastases · China | 3 | UNKNOWN | Mar 1, 2021 | 700 |
| NCT04213105Healthy People · China | 1 | UNKNOWN | Oct 31, 2020 | 144 |
| NCT04128163Osteoporosis, Postmenopausal · China | 3 | UNKNOWN | Aug 31, 2021 | 440 |
| NCT03651947Healthy People · China | 1 | Completed | Nov 17, 2018 | 168 |
How it is read
Names in the registry
- “QL1206”, 5 entries
Conditions, from the studies’ own filings
- Osteoporosis, 1 study
- Neoplasm Metastasis, 1 study
- Osteoporosis, Postmenopausal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.